Combinations of miRNAs with other classic serum markers, i.e., AFP, is another approach to increase sensitivity and specificity of blood-based early detection of HBV-HCC (117, 118), especially for atypical HCC cases with lower serum AFP levels. Here, AFP is linked to hepatocellular carcinoma.